RHYTHM BIOSCIENCES LIMITED Rhythm Biosciences Limited
Appendix 4D
Half-Year report
1. Company details | ||||
Name of entity: | Rhythm Biosciences Limited | |||
ABN: | 59 619 459 335 | |||
only | For the half-year ended 31 December 2021 | |||
Reporting period: | ||||
Previous period: | For the half-year ended 31 December 2020 | |||
2. Results for announcement to the market | ||||
2021 | 2020 | |||
use | $ | $ | ||
Up 118% to | 2,433,429 | 1,118,772 | ||
Oth r income from ordinary activities | ||||
Loss from ordinary activities after tax attributable to the owners of | ||||
Rhythm Biosciences Limited | Up 110% to | (4,220,697) | (2,013,923) | |
Comprehensive loss for the year attributable to the owners of Rhythm | ||||
Biosciences Limited | Up 110% to | (4,220,697) | (2,013,923) | |
Dividends | ||||
There were no dividends paid, recommended or declared during the period. | ||||
personal | ||||
Comments |
Comments on activities during the half-year are included in the Directors' Report in the Interim Financial Report attached.
3. Net tangible assets | ||||
Reporting | Previous | |||
period | period | |||
Cents | Cents | |||
Net tangible assets per ordinary security | 2.33 | 2.82 | ||
4. Control gained over entities
The Company established a 100% owned USA domiciled entity, IchorDX Inc, with the intent on accelerating international expansion activities.
For5. Loss of control over entities
Not applicable.
6. Details of associates and joint venture entities
Not applicable.
Rhythm Biosciences Limited
Appendix 4D
Preliminary final report
7. Audit qualification or review
Details of audit/review dispute or qualification (if any):
onlyThe financial statements have been reviewed and an unqualified conclusion has been issued.
8. Attachments
Details of attachments (if any):
The Interim Financial Report of Rhythm Biosciences Limited for the half-year ended 31 December 2021 is attached.
9. Signed
use | Date: 25 February 2022 |
Glenn Gilbert | |
personalFor | |
Managing Director |
For personal use only
RHYTHM BIOSCIENCES
LIMITED
(ASX: RHY)
INTERIM FINANCIAL REPORT
TO 31 DECEMBER 2021
Rhythm Biosciences Limited
Corporate Directory
31 December 2021
Directors
onlyCompany secretary Registered office
useShare register
A ditor
personalStock exchange listing For
Mr Otto Buttula (Executive Chairman)
Mr Glenn Gilbert (Managing Director)
Dr Trevor John Lockett
Mr Louis (Lou) James Panaccio
Mr Eduardo Vom
Dr Rachel David
Ms Andrea Steele
Bio21 Molecular Science & Biotechnology Institute 30 Flemington Road
Parkville VIC 3010 Australia
+ 61 3 8256 2880 (Phone)
Link Market Services Limited
QV1, Level 12, 250 St. Georges Terrace
Perth WA 6000
BDO Audit Pty Ltd
Collins Square
Tower 4
Level 18, 727 Collins Street
Melbourne VIC 3008
Rhythm Biosciences Limited shares are listed on the Australian Securities Exchange (ASX code: RHY)
2
Rhythm Biosciences Limited
Contents
31 December 2021
Directors' report Review of operations
Auditor's independence declaration
onlyStatement of profit or loss and other comprehensive income Statement of financial position
Statement of changes in equity Statement of cash flows
Notes to the financial statements Directors' declaration
Independent auditor's review report to the members of Rhythm Biosciences Limited
4
5
7
8
9
10
11
12
16
17
General information
useThe financial statements cover Rhythm Biosciences Limited as a consolidated entity consisting of Rhythm Biosciences Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Rhythm Biosciences Limited's functional and presentation currency.
Rhythm Biosciences Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road personalP rkville VIC 3010
For
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Rhythm Biosciences Ltd. published this content on 24 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 February 2022 00:00:01 UTC.
